Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.35 |
| ▸ | AR | P10275 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25374011 | 0.83 | AR (0.36) | AR | |
| SCHEMBL30542709 | 0.83 | AR (0.36) | AR | |
| SCHEMBL9601583 | 0.78 | AR (0.35) | AR | |
| SCHEMBL10433970 | 0.78 | AR (0.35) | AR | |
| SCHEMBL3203094 | 0.78 | AKR1B1 (0.39) | NLRP3CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10434361 | 0.77 | AR (0.36) | AR | |
| SCHEMBL10918901 | 0.76 | MTNR1A (0.37) | NLRP3ALDH1A1TP53IRAK4 | |
| SCHEMBL3204829 | 0.75 | FFAR1 (0.38) | CYP2C9 | |
| SCHEMBL3343457 | 0.70 | AR (0.45) | AR | |
| SCHEMBL13219199 | 0.70 | IRAK4 (0.43) | NLRP3CYP3A4CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070244318-A1 | Process for the Preparation of Levofloxacin Hemihydrate | RAO DAVULURI R | 2007-10-18 | — | — | US | disclosed |
| EP-1809637-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LEVOFLOXACIN HEMIHYDRATE | Neuland Laboratories Ltd (IN) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006048889-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LEVOFLOXACIN HEMIHYDRATE | NEULAND LABORATORIES LTD. (IN) | 2006-05-11 | — | — | WO | disclosed |
| EP-0206283-B1 | OPTICALLY ACTIVE PYRIDOBENZOXAZINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1993-01-27 | — | — | EP | disclosed |
| US-5142046-A | Optically active pyridobenzoxazine derivatives and intermediates thereof | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1992-08-25 | — | — | US | disclosed |
| US-5053407-A | OPTICALLY ACTIVE PYRIDOBENZOXAZINE DERIVATIVES AND ANTI-MICROBIAL USE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1991-10-01 | — | — | US | disclosed |
| US-4985557-A | OFLOXACIN INTERMEDIATE | DAIICHI SEIYAKU CO., LTD. (JP) | 1991-01-15 | — | — | US | disclosed |
| EP-0206283-A2 | Optically active pyridobenzoxazine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1986-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244318-A1 | Process for the Preparation of Levofloxacin Hemihydrate | RTF1, CYP2F1, CYP4F11 | NLRP3 916/4885AR 2713/4885CYP3A4 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.